miRNA / siRNA transfection
Versatile reagent for standard and challenging cells. Fully compatible with suspension cells and 3D spheroids. Highly efficient and safe.
Selected cells might prefer GREEN.
Viromer® BLUE was developed for the siRNA transfection and is optimized for binding the size of small oligonucleotides like miRNA and siRNA. It is based on a medium sized branched polymer and the neutral charge of Viromer BLUE : miRNA and siRNA transfection complexes results in no aggregation and high performance in suspension cells like primary microglia cells. Viromer® BLUE achieves the best miRNA or siRNA transfection results in classical cell lines widely used in cell biology such as HEK-293, HeLa and CHO as well as in challenging primary cells like mesenchymal stem cells, macrophages, monocytes, myoblasts and hepatocytes. By using Viromer® BLUE a highly efficient miRNA and siRNA transfection is possible without the use of enhancers. Based on an active endosome escape mechanism siRNA transfection becomes more efficient compared to standard reagents as more of introduced siRNA/miRNA molecules reach the cytoplasma. Due to lowest toxicity and superior efficiency, Viromer® BLUE turns a hardly-possible miRNA and siRNA transfection into a superior one.
Proprietary Viromer® BLUE miRNA and siRNA transfection technology has already convinced numerous research groups by providing excellent results on cell lines and primary cells that were thought to be impossible to transfect. siRNA transfection of human primary macrophages and human primary mesenchymal stem cells results in 70% knock down efficiency using Viromer® BLUE.
For primary skeletal myoblasts, primary hepatocytes, RAW264.7 mouse macrophages, melanoma cells, Hs74T gastric carcinoma cells as well as glioblastoma cell lines NCH82 and NCH149 a siRNA transfection efficiency >90% can be achieved using Viromer® BLUE.
Ingerslev et. al., Mol Metab., 2017
Brüser et. al., Sci Rep., 2017
Armento et. al., Int J Oncol., 2017
Smith et. al., Sci Rep., 2017
Ciechomska et. al., Eur J Clin Invest., 2017
Kawasaki et. al., J Pharmacol Sci., 2017
Park et. al., Int J Oncol., 2017
Hertsenberg et. al., PLoS ONE, 2017
Burai et. al., US Patent 20,170,050,967, 2017
Czirr et. al., J Exp Med., 2017
Haneklaus et. al., JBC, 2017
et. al., Cell Death & Differentiation, 2017
Morrison et.al., J. Vis. Exp., 2016
Decker et.al., J Clin Onc Exp Onc, 2016
Klingler et.al., Biochim Biophys Acta., 2016
Tasker et.al., JCI Insight., 2016
Ciechomska et.al., Sci Rep., 2016
Medunjanin et.al., Sci Rep., 2016
Yan et.al., Cell Rep, 2016
Ellert-Miklaszewska et. al., Oncogene 2016
Machacek et. al., J Immunol., 2016
Watanabe et. al., Proc Natl Acad Sci U S A., 2016
Paijo et. al., PLoS Pathog., 2016
Griss et. al., J Infect Dis, 2016
Robertson et. al., PLoS Biol, 2016
Ordelheide et. al., Molecular Metabolism, 2016
Ciechomska et.al., Arthritis Rheumatol, 2016
Chen et. al., Sci Signal., 2015
Kraus et.al., Mol Cell Endocrinol., 2015
Rane et.al., Br J Cancer, 2015
Zhang et.al., Oncogene, 2015
Salama et. al., PLoS One, 2014
Zekavati et. al., PLoS One, 2014